Fidelity Investments

With Fidelity Active ETFs, you can have the flexibility needed to adapt and transform based on market conditions with potential tax efficiencies. 

FidelityETF_BM_OTT_September2025

Stay up to date on the latest market news with daily analysis of the investing landscape, served up Brew-style.

Brew Markets

Morning Brew

Money with Katie

Morning Brew Daily 

Bossy

Per My Last Email

After Earnings

Our Future

CFO Brew

Healthcare Brew

HR Brew

IT Brew

Marketing Brew

Retail Brew

Tech Brew

Automakers

Commodities

Cryptocurrencies

Macro Economics

Stocks

Stock Market News

Explainers

Events

brewmarkets.com

When ChatGPT first launched, Public spotted an opportunity. They asked: How could this technology potentially benefit retail investors? And thus, Alpha was born in 2023. Think of it as a chat interface and research assistant for investing FAQs. Questions like “Why is this stock moving?” or “Can you show me an earnings report?” can be given a considered response, providing background data to help make faster decisions.

In fact, in recent years of AI being available for market questions, retail investors have been doing just that. Public found that with AI, 25% of members who use Public’s Alpha make a trade within three hours of asking a question.

But speed doesn’t necessarily beget accuracy. This begs the question: Where is the balance? With AI arriving in a big way on the investing scene, where will it be used outside of research? Early use cases are showing AI can help retail investors build customized portfolios based on the themes they’re interested in.

To learn more, Brew Markets’ Ann Berry sits down with Stephen Sikes, COO of Public, to discuss what’s next for AI usage in the retail investing space. Tune in to find out.

Speakers

Questions?

AI is reshaping how retail investors research, trade, and even build personalized portfolios—but speed doesn’t always guarantee accuracy. Join Brew Markets’ Ann Berry and Public COO Stephen Sikes as they explore where AI is adding value in investing today and where it’s headed next.

Light green key on a dark green background

(Fund)amental Tech: How Retail Investors Are Embracing AI

Lucy Brewster

A whole new race to corner the weight-loss drug market has begun—and Eli Lilly is pulling ahead of its rivals.

Big pharma companies are developing GLP-1 

 as opposed to the injections that are currently on the market. The reason that matters is pretty intuitive: A daily pill is much easier to take than a weekly shot, and 

, too. That would open up the weight-loss drug market to a whole new swath of potential customers and avert the supply chain challenges that have nagged the industry over the past few years.

In fact, oral weight-loss drugs could one day account for roughly a third of the overall GLP-1 market—a market that Guggenheim analysts predict could be worth 

There are no FDA-approved GLP-1 pills on the market right now, but that’s set to change in the next few months.

Eli Lilly announced yesterday that its new oral drug beat Novo Nordisk’s in 

, saying that it helped patients with Type 2 diabetes lower their blood sugar more than Novo's over 52 weeks. In addition, Eli Lilly’s pill caused those patients to lose 9% of their body weight, compared to 5% from Novo’s drug.

But Novo didn’t take the news lying down: The Danish pharma giant revealed its own numbers today, arguing that its “Wegovy pill” helped patients lose nearly 17% of body weight 

Novo Nordisk popped 6.29% today, while Eli Lilly rose 0.35%.

Novo Nordisk had the early lead in the GLP-1 market, but blew it after a slew of supply chain issues slowed down its rollout. It’s hoping to regain the top spot during the oral drug era, but analysts believe that Eli Lilly has a roughly three-year lead in the race to develop a pill.

But that race is far from over: Other pharma heavyweights like AstraZeneca and Structure Therapeutics are also developing their own versions of these pills.—

Slimming down is big business

Weight-loss wars

Weighing the options

Making sense of market moves